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Objective: Although skeletal muscle atrophy is common in critically ill patients, biomarkers 
associated with muscle atrophy have not been identified reliably. Titin is a spring-like protein 
found in muscles and has become a measurable biomarker for muscle breakdown. We 
hypothesized that urinary titin is useful for monitoring muscle atrophy in critically ill patients. 
Therefore, we investigated urinary titin level and its association with muscle atrophy in critically 
ill patients. 
Design: Two-center, prospective observational study 
Setting: Mixed medical/surgical intensive care unit (ICU) in Japan 
Patients: Nonsurgical adult patients who were expected to remain in ICU for >5 days 
Interventions: None 
Methods: Urine samples were collected on days 1, 2, 3, 5, and 7 of ICU admission. To assess 
muscle atrophy, rectus femoris cross-sectional area and diaphragm thickness were measured with 
ultrasound on days 1, 3, 5, and 7. Secondary outcomes included its relationship with ICU-
acquired weakness (ICU-AW), ICU Mobility Scale (IMS), and ICU mortality. 
Measurements and Main Results: Fifty-six patients and 232 urinary titin measurements were 
included. Urinary titin (normal range: 1–3 pmol/mg Cr) was 27.9 (16.8–59.6), 47.6 (23.5–82.4), 
46.6 (24.4–97.6), 38.4 (23.6–83.0), and 49.3 (27.4–92.6) pmol/mg Cr on days 1, 2, 3, 5, and 7, 
respectively. Cumulative urinary titin level was significantly associated with rectus femoris 
muscle atrophy on days 3–7 (p < 0.03), although urinary titin level was not associated with 
change in diaphragm thickness (p = 0.31–0.45). Furthermore, cumulative urinary titin level was 
associated with incidence of ICU-AW (p = 0.01) and ICU mortality (p = 0.02) but not with IMS 
(p = 0.18).  
Conclusions: In nonsurgical critically ill patients, urinary titin level increased 10–30 times 
compared with the normal level. The increased urinary titin level was associated with lower limb 
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Skeletal muscle atrophy is common in critically ill patients (1, 2). After intensive care unit (ICU) 
admission, muscle atrophy develops within 3 days and progressively worsens thereafter (3). In 
our previous study, upper and lower limb muscle mass of critically ill patients decreased by 
13%–21% within 7 days of admission (4). Muscle atrophy in ICU is associated with long-term 
functional impairment and weakness among ICU survivors (5). 
Although monitoring of muscle mass is important, reliable biomarkers for muscle 
atrophy are unavailable for critically ill patients. However, recently, an enzyme-linked 
immunosorbent assay (ELISA) kit was developed for detecting urinary N-terminal fragment of 
titin (6). Titin is a giant sarcomeric protein, which functions as a spring for muscle extension and 
viscoelasticity. Because urinary titin reflects muscle breakdown, it is used as a biomarker for 
diagnosing muscular dystrophy (7). In patients with muscular dystrophy, urinary titin level 
increases 100 times compared with that in healthy volunteers (normal range: 1–3 pmol/mg Cr). 
To the best of our knowledge, no study has investigated urinary titin level in critically ill patients 
and its association with muscle atrophy. 
We hypothesized that urinary titin will increase in critically ill patients and can be used 
to assess muscle atrophy. According to a study, surgical insult increased urinary titin level (8). 
Therefore, we investigated urinary titin level in nonsurgical critically ill patients. The aim of this 
exploratory study was to investigate the relationship between urinary titin level and limb muscle 
atrophy in nonsurgical critically ill patients. Secondary objectives were to assess its relationship 
with changes in diaphragm thickness, incidence of ICU-acquired weakness (ICU-AW), ICU 
5 
 
Mobility Scale (IMS), and ICU mortality. 
 
MATERIALS AND METHODS 
Study Design 
From May 2019 to February 2020, we conducted a two-center, prospective observational study at 
the mixed medical/surgical ICU of Tokushima University Hospital and Tokushima Prefectural 
Central Hospital. This study was approved both clinical research ethics committees of 
Tokushima University Hospital (approval number 2593) and Tokushima Prefectural Central 
Hospital (approval number 1739). This trial was registered as a clinical trial (UMIN-Clinical 
Trials Registry: 000031316). At the time of enrollment, written informed consent was obtained 
from patients or their authorized surrogate decision makers. 
Consecutive adult patients who were expected to remain in ICU for >5 days were 
enrolled. Patients were prospectively recruited within 12 h of ICU admission. Nonsurgical 
critically ill patients were included because surgical insult reportedly increased urinary titin level 
(Table S1) (8). We excluded patients based on the following exclusion criteria: surgery not 
including percutaneous abscess drainage, chest tube insertion, and tracheostomy in ICU; age of 
<18 years; current pregnancy; diagnosis of primary neuromuscular disease; trauma at the 
measurement point, and unclear ultrasound image. 
 
Urinary Titin Measurement 
The first urine sample was collected using a urethral catheter within 12 h of ICU admission and 
24-hour urine samples on days 2, 3, 5, and 7. Urinary titin was measured using an ELISA kit 
(27900 Titin N-Fragment Assay Kit, Immuno-Biological Laboratories Co. Ltd., Japan) (6). This 
kit is capable of measuring urinary N-terminal fragment of titin cleaved by calpain-3. This is a 
highly sensitive kit used to measure a whole range of biologically relevant protein levels in urine 
samples (9). The reference range was 1–3 pmol/mg Cr in healthy volunteers, which was 
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creatinine (Cr) corrected to adjust for various physiological conditions (6). We used cumulative 
urinary titin level (area under the curve of urinary titin level for individual patients) for 
comparison. 
Urine volume and concentration are influenced by kidney function, dehydration, age, 
and sex. Therefore, Cr correction is necessary in the measurement of titin level (6). We analyzed 
the influence of acute kidney injury (AKI) and renal replacement therapy because renal function 
is often impaired in critically ill patients. AKI was defined as Kidney Disease Improving Global 
Outcomes stages 1–3 without renal replacement therapy (RRT). Twenty-six and six patients 
were classified into AKI and RRT, respectively. Cr correction seems to attenuate the influence of 
AKI and RRT (Fig. 1). 
 
Ultrasonographic Measurement 
Rectus femoris muscle area and diaphragm thickness were evaluated with serial ultrasound 
measurements on days 1, 3, 5, and 7 of ICU admission. Recordings were discontinued at death or 
ICU discharge. Cross-sectional area of the rectus femoris muscle was evaluated at the midway 
between the anterior superior iliac spine and the proximal end of the patella. A transducer was 
placed perpendicularly to the long axis of the rectus femoris muscle with patients in the supine 
position under passive knee extension. Patients were divided into a high- or low-atrophy group 
on days 3, 5, and 7 of ICU admission based on the extent of muscle atrophy. The cutoff value 
was decided based on the median atrophy rate each day. 
The diaphragm was evaluated at the zone of apposition on the right chest wall. Its 
thickness was measured during the end-expiration phase. Beds were adjusted at a 30° angle. We 
excluded patients whose diaphragm was unclear or difficult to measure. Patients were divided 
into three groups according to the changes in diaphragm thickness: atrophy, unchanged, and 
increased. A 10% change in diaphragm thickness was regarded as the cutoff value in the three 
groups. Atrophy was first classified with >10% decrease in diaphragm thickness from day 1 to 
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the lowest value over the measurement period. Thereafter, increased thickness group was 
classified when >10% increase was observed. The rest of the patients were classified into the 
unchanged group, as previously reported (10). In the analysis, the unchanged group was 
compared with atrophy and increased groups and their combination because both increased and 
decreased diaphragm thickness significantly influence clinical outcomes (11).  
Rectus femoris cross-sectional area and diaphragm thickness were measured thrice, and 
the median value was used for evaluation. All measurements were conducted by two examiners. 
Intraclass and interclass correlation coefficients were 0.99 and 0.99 for rectus femoris cross-
sectional area and 0.95 and 0.95 for diaphragm thickness, respectively (Table S2). 
 
Physical Assessment and Mobilization 
When patients were awake and attentive, physical therapists evaluated the Medical Research 
Council (MRC) score and incidence of ICU-AW on days 1, 3, 5, and 7 of ICU admission. Intact 
level of consciousness and awareness was defined by patient’s response to at least three of five 
orders (12). ICU-AW was defined as an MRC score of <48 on two separate occasions, and 
patients with expected prehospital functional status of <48 were excluded (13). We used the 
incidence of ICU-AW following the last measurement for comparison. IMS is a measure of 
mobilization capabilities from 0 (lying in bed) to 10 (walking independently) (14). We evaluated 
maximum IMS score during the study period because the maximum level of mobility is an 
important prognostic factor (15). Two facilities in this study used the same progressive 
mobilization protocol (16). 
  
Outcomes  
Our primary outcome was the relationship between cumulative urinary titin level and rate of 
rectus femoris muscle atrophy on days 3, 5, and 7 of ICU admission. In secondary analysis, we 
evaluated the relationship between urinary titin level and change in diaphragm thickness 
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(atrophy, unchanged, and increased groups), incidence of ICU-AW, IMS, and ICU mortality. 
 
Statistical Analysis 
Continuous data are presented as mean ± standard deviation or median [interquartile range 
(IQR)], as appropriate, whereas categorical data are presented as number (%). Variables were 
compared using t-test the Mann–Whitney U-test for two-group comparison, and one-way 
analysis of variance or the Kruskal-Wallis test for three-group comparison. Post hoc correction 
for multiple comparisons was performed with Tukey’s or Steel–Dwass test. Changes in muscle 
mass were assessed by mixed-effect model for repeated measures (MMRM). MMRM was also 
used to evaluate the association between urinary titin level on day 1 and change in diaphragm 
thickness or rectus femoris cross-sectional area over time. We constructed receiver operating 
characteristic (ROC) curves to determine whether urinary titin level can discriminate ICU-AW.  
Because titin has not been investigated in critically ill patients, 60 patients were planned for 
enrollment based on a previous study (17). Data analyses were conducted using JMP version 
13.1.0 (SAS Institute Inc., Cary, NC). All statistical tests were two tailed, and the chosen type 1 
error rate was p-value of <0.05. 
 
RESULTS 
In total, 62 patients were recruited, among whom 56 remained in the study till day 3, 40 till day 
5, and 24 till day 7 of ICU admission (Fig. S1). Six patients were excluded due to only one 
measurement, with 56 patients and 232 urinary titin level measurements in the final analysis. 
Patient characteristics are summarized in Table 1. The mean age of the patients was 72 ± 13 
years, and 33 patients were male. Acute Physiology and Chronic Health Evaluation II score was 
25 (IQR, 19–29) and length of ICU stay was 6 days (IQR, 4–9 days). Thirty-seven (66%) 
patients were mechanically ventilated, with additional 13 (23%) patients under noninvasive 
positive pressure ventilation or high-flow nasal cannula. The main reasons for admission were 
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respiratory failure (n = 23, 41%), heart failure (n = 12, 21%), non-respiratory sepsis (n = 6, 
11%), and cardiac arrest (n = 6, 11%), with 23 (41%) patients meeting the sepsis III criteria.  
 
Trend of Urinary Titin Level 
Urinary titin level was 27.9 (16.8–59.6), 47.6 (23.5–82.4), 46.6 (24.4–97.6), 38.4 (23.6–83.0), 
and 49.3 (27.4–92.6) pmol/mg Cr on days 1, 2, 3, 5, and 7 of ICU admission, respectively (Fig. 
1a). In 19 (34%) patients, the highest urinary titin level was >100 pmol/mg Cr, whereas 4 
patients had a level of >300 pmol/mg Cr. Urinary titin level significantly increased from day 1 to 
days 2–7 of ICU admission (p ≤ 0.02). The trend of urinary titin level is shown for each 
admission in Table S1, and patients who met the sepsis III criteria had a higher urinary titin level 
than non-sepsis patients (sepsis vs non-sepsis, 93.0 vs 57.9 pmol/mg Cr, p = 0.02). 
 
Relationship between Urinary Titin Level and Rectus Femoris Cross-Sectional Area 
A total of 176 images of 56 patients were analyzed. Rectus femoris cross-sectional area changed 
progressively by −8.6% ± 4.9%, −13.8% ± 5.9%, and −18.2% ± 5.6% on days 3, 5, and 7 of ICU 
admission, respectively (p < 0.01; MMRM, Fig. 1b). Regarding high and low-atrophy groups, 
the median cutoff value was set at −8.6%, −12.0%, and −17.5% for days 3, 5, and 7 of ICU 
admission, respectively. There was a significant difference in cumulative urinary titin level 
between these groups: 138.2 (78.9–247.3) vs 63.9 (29.2–104.3) pmol/mg Cr (p < 0.01) on day 3, 
289.9 (166.2–411.2) vs 111.8 (72.2–229.6) pmol/mg Cr (p < 0.01) on day 5, and 515.4 (241.1–
799.1) vs 192.4 (135.9–326.2) pmol/mg Cr (p = 0.03) on day 7 of ICU admission (high vs low-
atrophy group; Fig. 2). The change in rectus femoris cross-sectional area was associated with 
urinary titin level on day 1 (Titin p = 0.01, Time p < 0.01; MMRM). The correlation is presented 
in Fig. S3. 
 
Relationship between Urinary Titin Level and Diaphragm Thickness 
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A total of 156 diaphragm images of 50 patients were analyzed. Six patients were excluded due to 
unsuccessful measurement. Diaphragm thickness decreased by >10% in 32 (64%) patients, 
remained unchanged in 12 (24%), and increased by >10% in 6 (12%). In total, diaphragm 
thickness changed by −4.9% ± 15.8%, −8.0% ± 16.9%, and −15.4% ± 10.2% on days 3, 5, and 7 
of ICU admission, respectively (p < 0.01; MMRM). There was no significant difference in 
cumulative urinary titin level: 147.9 (79.0–257.8) vs 192.4 (104.0–367.5) pmol/mg Cr (p = 
0.33); 426.1 (140.8–578.2) pmol/mg Cr (p = 0.45); 206.5 (99.3–440.8) pmol/mg Cr, (p = 0.31), 
respectively (unchanged vs atrophy, increased, and combination groups, Fig. 3a). The median 
difference was 44.9 [95% confidence interval (CI), −63.4–186.2], 230.0 (95% CI, −144.5–
527.3), and 52.0 (95% CI, −57.5–223.9) pmol/mg Cr in atrophy, increased, and combination 
groups, respectively. The change in diaphragm thickness was not associated with urinary titin 
level on day 1 (Titin p = 0.51, Time p = 0.01; MMRM). 
 
Relationship between Urinary Titin Level and Other Outcomes 
We assessed ICU-AW in 35 of the 56 included patients; subsequently, 9 patients that met the 
diagnostic criteria of ICU-AW. Cumulative urinary titin level was significantly higher in patients 
with ICU-AW: 314.1 (181.5–464.7) in patients with ICU-AW vs 86.6 (66.3–171.1) pmol/mg Cr 
in patients without ICU-AW (p = 0.01; Fig. 3b). The area under the curve of ROC curves of 
ICU-AW were 0.78 (95% CI, 0.61–0.95) for cumulative urinary titin level and 0.75 (95% CI, 
0.56–0.94) cumulative urinary titin level on day 2 of ICU admission (Fig. S2). The maximum 
IMS was not associated with cumulative urinary titin level: 191.8 (96.9–366.9) in IMS 0–1 vs 
116.7 (60.8–368.4) pmol/mg Cr in IMS 2–10 (p = 0.18). On the other hand, cumulative urinary 
titin level was associated with ICU mortality: 466.5 (206.7–1055.9) for dead patients vs 152.9 





In this two-center prospective observational study, we found that urinary titin level increased in 
nonsurgical critically ill patients, and cumulative urinary titin level reflected the extent of rectus 
femoris muscle atrophy. In addition, cumulative urinary titin level was associated with the 
incidence of ICU-AW and ICU mortality. Our study indicates urinary titin level can be used to 
evaluate catabolism and muscle atrophy in critically ill patients. To the best of our knowledge, no 
study has investigated urinary titin level in critically ill patients. 
Urinary titin level was 10–30 times higher in critically ill patients than in healthy 
volunteers (1–3 pmol/mg Cr), and 34% of patients had >100 pmol/mg Cr, which is the equivalent 
level in muscular dystrophy (7). Catabolism was clearly ongoing in critically ill patients. As a 
biomarker, urinary titin level may rapidly respond to the patient’s status and can reflect ongoing 
catabolism due to the high urinary titin level on admission day and significant increase from day 
2 of admission. Oshida et al. suggested urinary titin level may reflect skeletal muscle atrophy in 
nonalcoholic fatty liver disease because this level was higher in low-muscle mass group (18). In 
our study, we clearly observed that urinary titin level is a good biomarker for ongoing catabolism 
and subsequent muscle atrophy in critically ill patients. As a result, it is reasonable that higher 
cumulative urinary titin level is associated with ICU-AW and ICU mortality. 
Urinary titin level can be a good biomarker to diagnose ICU-AW, which is closely 
related to muscle atrophy (19). Because ICU-AW is established by evaluating volitional 
measurement (20), its use as a biomarker may help in identifying high-risk patients of ICU-AW 
including unconscious patients at an early phase. In a study, neurofilament level was higher in 
ICU-AW, but its peak was observed on day 7 (5–14) of ICU admission (21). On the other hand, 
urinary titin level significantly increased from day 2 of ICU admission, and the level on day 2 
showed good discriminative power. This is because muscle damage occurs more rapidly than 
neural damage in critically ill patients (22). Creatine phosphokinase (CK) might also be one of 
the candidate biomarkers for ICU-AW. However, it was not useful in identifying ICU-AW (23) 
because CK leaks from various tissues such as the brain as well as mitochondria (24). In the 
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diagnosis of muscular dystrophy, CK showed high false-positive rates (25) and urinary titin level 
was a better biomarker (9). Titin is a functional protein as actin and myosin, unlike CK. 
Therefore, urinary titin level represented deteriorated muscle function in critically ill patients. 
In this study, we obtained evidence that links elevated urinary titin level to rectus 
femoris muscle atrophy but not to diaphragm thickness. Because the quadriceps femoris muscle 
is the most voluminous muscle of the body and is a good indicator of whole-body muscle mass 
(26), it is understandable that elevated urinary titin level was correlated with rectus femoris 
muscle atrophy. On the other hand, the amount of muscle in the diaphragm is lesser than that in 
the quadriceps femoris muscle, with different physiologies (27). Moreover, the diaphragm is not 
the only respiratory muscle to be atrophied (10). Thus, we could not observe a significant 
association between change in diaphragm thickness and cumulative urinary titin level. However, 
a study suggested that titin is involved in diaphragm atrophy (28). Therefore, we need to create a 
diaphragm-specific titin antibody akin to the cardiac-specific antibody in use (29).  
The current standard for diagnosing muscle atrophy is ultrasound, which can be used 
noninvasively at bedside (30). Ultrasound is the most reliable method for monitoring muscle 
mass because it is not influenced by fluid balance in critically ill patients (31). However, it 
requires measurement equipment, time, and skills. On the other hand, because measuring urinary 
titin level is simple, noninvasive, and needs no equipment, it may be more helpful for critically 
ill patients. Based on the urine test, we corrected kidney function by dividing urinary creatine 
(pmol/mg Cr). The influence of AKI seems small, although corrected urinary titin differed on 
day 7 of ICU admission due to limited number of patients (Fig. 1). Urinary titin level seemed to 
be corrected in patients requiring RRT because the levels of urinary titin and Cr were higher 
without correction. However, this result should be carefully interpreted because the removal ratio 
may depend on the dialysis membrane used for RRT. 
Urinary titin level is an emerging biomarker gaining attention in many fields (9). Its use 
may bring a paradigm shift in the muscle mass monitoring system, an approach that attenuates 
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muscle atrophy in critically ill patients. Despite the potential role of titin, it is not routinely 
available now. It is possible to create a spot urine test because urinary titin level does not 
fluctuate during the day (9). It is important to be aware about the catabolic state and identify 
muscle atrophy and ICU-AW to initiate early rehabilitation and nutritional support, which may 
improve long-term outcomes. 
 
Limitations 
First, this study had a small sample size, particularly in the analysis of diaphragm thickness. 
Second, the primary urinary titin level depends on the time of urine collection from the onset of 
the disease and does not reflect the normal state of patients. Lastly, although urinary titin level 
was associated with rectus femoris muscle atrophy, it showed a wide range of values. We cannot 




In nonsurgical critically ill patients, urinary titin level increased 10–30 times compared with the 
normal level. The increased urinary titin level reflected lower limb muscle atrophy. Furthermore, 
urinary titin level was associated with incidence of ICU-AW and ICU mortality. Urinary titin 
level could be used as a biomarker for catabolism and subsequent muscle atrophy. 
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Figure 1. Influence of acute kidney injury or renal replacement therapy. A, Urinary titin 
(pmol/L). B, Urinary Creatinine (mg/dL). C, Urinary titin (pmol/mg Cr). AKI = acute kidney 
injury, RRT = renal replacement therapy, KDIGO = Kidney Disease Improving Global 
Outcomes. AKI was defined as KDIGO stages 1–3 without RRT. Number of patients on days 3, 
5, and 7 of ICU admission was 24, 16, and 10 for normal kidney function; 26, 18, and 8 for AKI; 
and 6, 6, and 6 for RRT, respectively. 
 
Figure 2. Time course of urinary titin level and muscle atrophy. A, Urinary titin level was higher 
than the normal level (1–3 pmol/mg Cr), with significant elevation from day 1 to days 2–7 of 
ICU admission (p ≤ 0.02). B, Rectus femoris CSA and diaphragm thickness significantly 
decreased. ICU = intensive care unit, CSA = cross-sectional area. Data are expressed as median 
(interquartile range). The number of patients on each studied day is shown below the graph. 
 
Figure 3. Relationship between cumulative urinary titin level and rectus femoris muscle atrophy 
on days 3, 5, and 7 of ICU admission. We evaluated the relationship between cumulative urinary 
titin level and the extent of muscle atrophy on days 3, 5, and 7 of ICU admission. Patients were 
divided into two groups (high and low atrophy) based on the median cutoff value of each day. 
Cumulative urinary titin level was associated with rectus femoris muscle atrophy (p < 0.01, p < 
0.01, p = 0.03 on days 3, 5, and 7 of ICU admission, respectively). 
 
Figure 4. Relationship between cumulative urinary titin level and diaphragm atrophy or 
incidence of ICU-AW. ICU-AW, intensive care unit-acquired weakness. Change in diaphragm 
thickness and incidence of ICU-AW was assessed in 50 and 35 patients, respectively. Cumulative 
urinary titin level was not associated with change in diaphragm thickness (p = 0.31–0.45), but it 




Supplemental File Legends 
Figure S1. Flow chart of patients included in this study. Sixty-two patients were recruited, and 56 
were included in the analysis. 
 
Figure S2. Titin-relayed ROC curves for incidence of ICU-AW. We show ROC curves for ICU-
AW: A. cumulative urinary titin level B. urinary titin level on day 2 of ICU admission. ICU-AW 
= intensive care unit-acquired weakness, ROC = receiver operating characteristic, AUC = area 
under the curve, CI = confidence interval. ICU-AW was identified in 9 of 35 patients. AUC was 
0.78 (95% CI, 0.61–0.95) for cumulative urinary titin level and 0.75 (95% CI, 0.56–0.94) for 
urinary titin level on day 2 of ICU admission. 
 
Figure S3. Relationship between cumulative urinary titin level and rectus femoris muscle or 
diaphragm atrophy. A–C. Rectus femoris muscle atrophy on days 3, 5, and 7 of ICU admission. 
D–F. Diaphragm atrophy on days 3, 5, and 7 of ICU admission. Cumulative urinary titin level 
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TABLE 1 Patient Characteristics (n = 56) 
Variables Overall (n = 56) 
Age, years (mean [SD]) 72 ± 13 
Gender (Men), n (%) 33 (59%) 
Body mass index, kg/m2  20.7 (18.1–24.1) 
SOFA 6 (4–10) 
APACHE II 25 (19–29) 
Length of ICU stay, days  6 (4–9) 
Mortality in the ICU, n (%) 8 (14%) 
ICU admission reasons, n (%) 
Respiratory failure 23 (41%) 
Heart failure 12 (21%) 
Sepsis, non-respiratory 6 (11%) 
Cardiac arrest 6 (11%) 
Trauma 5 (9%) 
Neurologic 4 (7%) 
SD = standard deviation, SOFA = Sequential Organ Failure Assessment, APACHE = Acute 
Physiology and Chronic Health Evaluation, ICU = intensive care unit, IQR = interquartile range 
Data were presented as median (IQR) unless otherwise indicated. 
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TABLE S1 Urinary Titin Level by ICU Admission Reasons 
ICU = intensive care unit, IQR = interquartile range 
*One cardiothoracic surgery was shown to explain urinary titin is increased after the surgery (aortic arch replacement). 
Data were presented as median (IQR). 
ICU admission reasons n (day 3, 5, 7) Day 1 Day 2 Day 3 Day 5 Day 7 
Respiratory failure 23, 17, 11 31.0 (16.8–48.9) 32.8 (18.2–60.2) 45.6 (27.7–93.0) 33.2 (15.7–91.3) 35.1 (19.6–159.8) 
Heart failure 12, 8, 3 27.2 (8.6–52.7) 26.7 (17.2–66.7) 30.6 (17.8–96.7) 35.1 (18.1–57.4) 68.4 (60.2–73.1) 
Sepsis, non-respiratory 6, 4, 2 89.2 (51.6–123.1) 94.2 (51.0–133.7) 97.8 (41.7–160.0) 140.6 (50.7–501.8) 277.9 (80.9–474.8) 
Cardiac arrest 6, 5, 4 20.6 (13.2–29.4) 65.7 (30.8–94.6) 47.6 (25.2–73.3) 42.0 (26.0–92.8) 49.6 (20.3–108.3) 
Trauma 5, 3, 2 32.9 (20.8–87.4) 44.9 (23.6–110.2) 50.6 (11.1–129.0) 24.3 (24.0–136.5) 64.4 (33.7–95.1) 
Neurologic 4, 3, 2 15.6 (13.2–51.0) 68.8 (24.9–117.1) 57.6 (25.0–84.9) 42.2 (24.1–77.9) 35.0 (33.9–36.1) 
Cardiothoracic surgery* 1, 1, 1 99.6 – 84.8 55.8 54.2 
TABLE S2 Reproducibility of Measurements 
CI = confidence interval, CSA = cross-sectional area 
Reproducibility was assessed for 56 patients at 176 measurements in rectus femoris muscle, and 
50 patients at 156 measurements in diaphragm. The Pearson correlation coefficient and Bland-
Altman plot were determined by using JMP statistical software version 13.1.0 (SAS Institute 
















  Correlation coefficient  Bland-Altman 95% CI 
Variables r p 
 
Bias 95% CI 
Intra-observer reproducibility      
Rectus femoris CSA 0.99 < 0.01  0.017 ± 0.029 -0.039 to 0.074 
  Diaphragm thickness 0.95 < 0.01  0.008 ± 0.013 -0.017 to 0.034 
Inter-observer reproducibility      
  Rectus femoris CSA 0.99 < 0.01  0.019 ± 0.024 -0.029 to 0.067 
  Diaphragm thickness 0.95 < 0.01  0.014 ± 0.013 -0.012 to 0.039 
Figure S1. Flow chart of patients included in this study. Sixty-two patients were recruited, and 
















Figure S2. Relationship between cumulative urinary titin level and rectus femoris muscle or diaphragm atrophy. A–C. Rectus femoris 
muscle atrophy on days 3, 5, and 7 of ICU admission. D–F. Diaphragm atrophy on days 3, 5, and 7 of ICU admission. Cumulative 
urinary titin level was associated with rectus femoris muscle atrophy (p ≤ 0.03) but not with diaphragm atrophy (p = 0.20–0.64). 
 
Figure S3. Titin-relayed ROC curves for occurrence of ICU-AW. A. Cumulative urinary titin 
level. B. Urinary titin level on day 2 of ICU admission. ICU-AW = intensive care unit-acquired 
weakness, ROC = receiver operating characteristic, AUC = area under the curve, CI = 
confidence interval. ICU-AW was identified in 9 of 35 patients. AUC was 0.78 (95% CI, 0.61–
0.95) at the cumulative urinary titin level (Cut-off by Youden index: 181.5 pmol/mg Cr, 
sensitivity: 78%, specificity: 77%) and 0.75 (95% CI, 0.56–0.94) at the urinary titin level on day 
2 of ICU admission (Cut-off by Youden index: 64.8 pmol/mg Cr, sensitivity: 78%, specificity: 
81%). 
 
